Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imatinib
Drug ID BADD_D01136
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status approved
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D08066
MeSH ID D000068877
PubChem ID 5291
TTD Drug ID D0AZ3C
NDC Product Code 63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII BKJ8M8G5HI
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C29H31N7O
CAS Registry Number 152459-95-5
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic myeloid leukaemia recurrent16.01.07.003; 01.10.07.0030.002071%Not Available
Graft versus host disease in gastrointestinal tract07.11.01.027; 12.02.09.028; 10.02.01.0590.000112%Not Available
Internal haemorrhage24.07.01.0720.000414%Not Available
Unmasking of previously unidentified disease08.01.03.0800.000224%Not Available
Infantile apnoea22.11.02.004; 18.04.15.0030.000112%Not Available
Oral pigmentation07.05.05.0240.000112%Not Available
Acute aortic syndrome24.02.03.0050.000224%Not Available
Acute myeloid leukaemia refractory16.01.05.008; 01.10.05.0080.000224%Not Available
Bone giant cell tumour benign16.11.02.003; 15.09.01.0110.000112%Not Available
Cerebral venous sinus thrombosis24.01.04.021; 17.08.03.0060.000168%Not Available
Congestive hepatopathy09.01.06.027; 02.05.04.0180.000168%Not Available
Cutaneous T-cell lymphoma23.07.04.029; 16.17.03.002; 01.11.03.0020.000224%Not Available
Dilated cardiomyopathy02.04.01.0170.000448%Not Available
Erythrocyanosis24.03.01.008; 23.06.05.0110.000224%Not Available
Follicular lymphoma stage III16.28.08.003; 01.15.08.0030.000112%Not Available
Gastrointestinal angiectasia24.03.03.048; 07.15.04.0090.000280%Not Available
Graves' disease06.09.04.009; 05.02.02.009; 10.04.08.0140.000112%Not Available
Growth failure15.03.05.015; 14.03.02.030; 05.03.02.0060.000168%Not Available
Haemoperitoneum24.07.02.065; 12.01.17.007; 07.07.02.0070.000224%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hepatic cytolysis09.01.07.0360.000336%Not Available
Histiocytic sarcoma16.21.04.004; 01.13.04.0040.000224%Not Available
Hyperleukocytosis01.02.01.0180.000224%Not Available
Hypersensitivity pneumonitis22.01.01.027; 10.01.03.0560.000112%Not Available
Illness08.01.03.091--Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000336%Not Available
Immune-mediated hepatitis09.01.07.037; 10.02.01.0850.000168%Not Available
Laryngeal squamous cell carcinoma22.08.02.012; 16.19.03.0040.000112%Not Available
Loss of therapeutic response08.06.01.0410.000604%Not Available
Masticatory pain15.03.04.0220.000112%Not Available
The 31th Page    First    Pre   31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene